Regardless of which inhalant is used, inhaling vapours or gases can lead to injury or death. One major risk is hypoxia (lack of oxygen), which can occur due to inhaling fumes from a plastic bag, or from using proper inhalation mask equipment (., a medical mask for nitrous oxide) but not adding oxygen or room air. Another danger is freezing the throat. When a gas that was stored under high pressure is released, it cools abruptly and can cause frostbite if it is inhaled directly from the container. This can occur, for example, with inhaling nitrous oxide. When nitrous oxide is used as an automotive power adder , its cooling effect is used to make the fuel-air charge denser. In a person, this effect is potentially lethal). Many inhalants are volatile organic chemicals and can catch fire or explode, especially when combined with smoking. As with many other drugs, users may also injure themselves due to loss of coordination or impaired judgment, especially if they attempt to drive.
mg/day inhaled via jet nebulizer either once daily or divided into 2 doses. The maximum manufacturer recommended total dose is 1 mg/day. The National Asthma Education and Prevention Program Expert Panel defines low dose therapy for budesonide inhalation suspension as mg/day, medium dose therapy as 1 mg/day, and high dose therapy as 2 mg/day for children ages 5 to 11 years. Titrate to the lowest effective dose once asthma stability is achieved. Prolonged use of high doses, ., 2 mg/day, may be associated with additional adverse effects.
Dr. Rymer is currently researching regulation of movement in normal and neurologically disordered human subjects, including sources of altered motoneuronal behavior in hemispheric stroke survivors, using electro-physiological, pharmacological, and biomechanical techniques. He currently serves as Director of the Single Motor Unit Laboratory of the Shirley Ryan AbilityLab (SRALab, formerly known as the Rehabilitation Institute of Chicago, or RIC). From 1987-2017 he served as Director of the Sensory Motor Performance Program at RIC, and was RIC’s Vice President for Research from 2008-2014. He is the most senior scientist at SRALab and the founder of many of its current research programs. Dr. Rymer has established himself as one of the most successful mentors of junior faculty, and has been able to relate to the many backgrounds that can contribute to rehabilitation research. In addition to his roles at SRALab, he holds appointments as Professor of PM&R, Physiology, and Biomedical Engineering at the Northwestern University Feinberg School of Medicine.